Roman Butler Fullerton & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7M Buy
7,341
+33
+0.5% +$33.5K 1.92% 10
2025
Q4
$7.95M Buy
7,308
+135
+2% +$129K 2.08% 7
2025
Q3
$5.84M Sell
7,173
-1,800
-20% -$1.34M 1.57% 11
2025
Q2
$7.29M Buy
8,973
+249
+3% +$193K 2.15% 7
2025
Q1
$6.61M Sell
8,724
-975
-10% -$811K 2.56% 6
2024
Q4
$7.84M Sell
9,699
-328
-3% -$272K 2.49% 6
2024
Q3
$9.16M Buy
10,027
+122
+1% +$110K 2.76% 6
2024
Q2
$9.31M Buy
9,905
+64
+0.7% +$51.2K 3.01% 6
2024
Q1
$7.2M Buy
9,841
+53
+0.5% +$37.7K 2.7% 7
2023
Q4
$6.26M Sell
9,788
-178
-2% -$104K 2.44% 7
2023
Q3
$6.07M Buy
9,966
+84
+0.9% +$43.3K 2.87% 6
2023
Q2
$4.48M Buy
9,882
+554
+6% +$232K 2.06% 7
2023
Q1
$3.59M Sell
9,328
-1,469
-14% -$495K 1.79% 8
2022
Q4
$3.86M Sell
10,797
-11
-0.1% -$3.9K 2% 7
2022
Q3
$3.54M Sell
10,808
-1,853
-15% -$587K 2.25% 6
2022
Q2
$4.2M Buy
12,661
+4,833
+62% +$1.45M 2.33% 5
2022
Q1
$2.24M Buy
7,828
+4,507
+136% +$1.16M 1.04% 24
2021
Q4
$917K Buy
3,321
+1
+0% +$254 0.41% 75
2021
Q3
$793K Sell
3,320
-23
-0.7% -$5.68K 0.37% 77
2021
Q2
$767K Buy
3,343
+2
+0.1% +$402 0.37% 87
2021
Q1
$621K Buy
3,341
+443
+15% +$86.7K 0.31% 99
2020
Q4
$489K Buy
2,898
+226
+8% +$33.7K 0.29% 98
2020
Q3
$395K Buy
2,672
+2
+0.1% +$310 0.26% 102
2020
Q2
$438K Buy
2,670
+1
+0% +$153 0.31% 98
2020
Q1
$370K Buy
2,669
+2
+0.1% +$275 0.33% 93
2019
Q4
$351K Buy
2,667
+1
+0% +$116 0.23% 128
2019
Q3
$298K Sell
2,666
-329
-11% -$36.6K 0.21% 137
2019
Q2
$332K Buy
2,995
+4
+0.1% +$471 0.22% 133
2019
Q1
$388K Buy
2,991
+1,030
+53% +$125K 0.27% 120
2018
Q4
$227K Buy
+1,961
New +$219K 0.19% 143

Other funds holding LLY

Roman Butler Fullerton & Co's LLY Position: Q1 2026 in Review

Roman Butler Fullerton & Co increased its Eli Lilly (LLY) stake by 0.45% in Q1 2026, buying an estimated $33.5K and bringing the position to 7,341 shares worth $7M. The position accounts for 1.92% of the portfolio, ranked #10.

Roman Butler Fullerton & Co first reported a position in LLY in Q4 2018 and has held it in 30 quarters since. The position peaked at $9.31M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Roman Butler Fullerton & Co held 7,341 shares of Eli Lilly worth $7M as of Q1 2026.
  • Roman Butler Fullerton & Co bought 33 Eli Lilly shares in Q1 2026, an estimated $33.5K.
  • Eli Lilly made up 1.92% of Roman Butler Fullerton & Co's portfolio in Q1 2026, its #10 holding.
  • Roman Butler Fullerton & Co first reported a position in Eli Lilly in Q4 2018 and has held it in 30 quarters since.
  • Roman Butler Fullerton & Co's Eli Lilly position peaked at $9.31M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q1 2026, filed 30 Apr 2026.